Objective: The study aimed to evaluate the impact of the different types of prostate involvement at the time of radical cystoprostatectomy (RCP). Methods: Data from 893 male patients treated with RCP at a referral center for bladder cancer (BCa) were assessed. Prostatic urothelial carcinoma (PUC) was stratified as stromal vs. urethral/duct involvements. Multivariable Cox regression analyses were built to test the impact of the presence of incidental prostate cancer (PCa) and PUC on survival outcomes. Results: PCa was present in 319 (35.7%) RCP patients, of which 45 (14.1%) had significant PCa disease. PUC was identified in 181 patients (20%): 75 (41.1%) with urethral/duct involvement and 106 (58.6%) with stromal. Within a median follow-up of 72 months, stromal PUC, but not the other forms of PUC or PCa, was associated with worse survival outcomes. In multivariable analyses adjusted for the effects of standard features, stromal PUC remained associated with recurrence (hazards ratio [HR] 2.01, p = 0.03), cancer-specific mortality (HR 1.65, p = 0.01), and overall mortality (HR 1.45, p = 0.03). Conclusion: Prostatic stromal invasion with urothelial carcinoma confers a poor survival expectation to BCa patients after surgical treatment. Conversely, other type of urothelial prostatic invasions or the presence of concomitant PCa does not seem to be associated with differences in survival outcomes.

Keywords:
Incidental, Prostate cancer, Bladder cancer, Radical cystectomy
1.
D”Agostino D, Racioppi M, Pugliese D, Ragonese M, Di Gianfrancesco L, Filianoti A, et al: Postoperative quality of life in patients with ileal neobladder at short-, intermediate- and long-term follow-up. Urol Int 2016;97:54-60.
2.
Wolters M, Oelke M, Lutze B, Weingart M, Kuczyk MA, Chaberny IF, et al: Deep surgical site infections after open radical cystectomy and urinary diversion significantly increase hospitalisation time and total treatment costs. Urol Int 2016, Epub ahead of print.
3.
Moschini M, Simone G, Stenzl A, Gill IS, Catto J: Critical review of outcomes from radical cystectomy: can complications from radical cystectomy be reduced by surgical volume and robotic surgery? Eur Urol Focus 2016, DOI: 10.1016/j.euf.2016.03.001.
4.
Mayr R, May M, Burger M, Martini T, Pycha A, Dechet C, et al: The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder. Urol Int 2014;93:303-310.
5.
Walsh PC, Schlegel PN: Radical pelvic surgery with preservation of sexual function. Ann Surg 1988;208:391-400.
6.
Colombo R, Pellucchi F, Moschini M, Gallina A, Bertini R, Salonia A, et al: Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. World J Urol 2015;33:1389-1395.
7.
Ong CH, Schmitt M, Thalmann GN, Studer UE: Individualized seminal vesicle sparing cystoprostatectomy combined with ileal orthotopic bladder substitution achieves good functional results. J Urol 2010;183:1337-1341.
8.
Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al: Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2016;pii:S0302-2838(16)30290-1.
9.
Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell'Oglio P, et al: Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: a 20-year single center experience. Eur J Surg Oncol 2016;42:735-743.
10.
Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, et al: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012;61:854-855.
11.
Bruins HM, Djaladat H, Ahmadi H, Sherrod A, Cai J, Miranda G, et al: Incidental Prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens. J Urol 2013;190:1704-1709.
12.
Yang X, Monn MF, Liu L, Liu Y, Su J, Lyu T, et al: Incidental prostate cancer in Asian men: high prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy. Prostate 2015;75:845-854.
13.
Pignot G, Salomon L, Neuzillet Y, Masson-Lecomte A, Lebacle C, Patard JJ, et al: Clinicopathological characteristics of incidental prostate cancer discovered from radical cystoprostatectomy specimen: a multicenter French study. Ann Surg Oncol 2014;21:684-690.
14.
Barbisan F, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Kirkali Z, et al: Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer? BJU Int 2009;103:1058-1063.
15.
Pignot G, Salomon L, Lebacle C, Neuzillet Y, Lunardi P, Rischmann P, et al: Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study. BJU Int 2015;115:87-93.
16.
Pan J, Xue W, Sha J, Yang H, Xu F, Xuan H, et al: Incidental prostate cancer at the time of cystectomy: the incidence and clinicopathological features in Chinese patients. PLoS One 2014;9:e94490.
17.
Breyer J, Denzinger S, Otto W, Bründl J, Gierth M, Fritsche HM, et al: Outcome of patients with pathological tumor stage T3 urothelial carcinoma of the bladder following radical cystectomy in a single-center series with 116 patients. Urol Int 2014;93:311-319.
18.
Ayyathurai R, Gomez P, Luongo T, Soloway MS, Manoharan M: Prostatic involvement by urothelial carcinoma of the bladder: clinicopathological features and outcome after radical cystectomy. BJU Int 2007;100:1021-1025.
19.
Fossati N, Passoni NM, Moschini M, Gandaglia G, Larcher A, Freschi M, et al: Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU Int 2016;117:740-747.
20.
Welch HG, Gorski DH, Albertsen PC: Trends in metastatic breast and prostate cancer - lessons in cancer dynamics. N Engl J Med 2015;373:1685-1687.
21.
Moschini M, Luzzago S, Cazzaniga W, Cucchiara V, Bandini M, Damiano R, et al: Impact of stage migration on bladder cancer: a slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years. Clin Genitourin Cancer 2016, DOI: 10.1016/j.clgc.2016.07.024.
22.
Hounsome LS, Verne J, McGrath JS, Gillatt DA: Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998-2010. Eur Urol 2015;67:1056-1062.
23.
Montironi R, Cheng L, Mazzucchelli R, Scarpelli M, Kirkali Z, Montorsi F, et al: Critical evaluation of the prostate from cystoprostatectomies for bladder cancer: insights from a complete sampling with the whole mount technique. Eur Urol 2009;55:1305-1309.
24.
Damiano R, Di Lorenzo G, Cantiello F, De Sio M, Perdonà S, D'Armiento M, et al: Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol 2007;52:648-657.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.